Saniona Announces Partnership with the Foundation for Prader-Willi Research (FPWR) to Support its Prader-Willi Syndrome (PWS) Clinical Trial with Tesomet
April 19, 2021
Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced it has entered into a partnership with the Foundation for Prader-Willi Research (FPWR) to increase awareness within FPWR’s community about Saniona’s Phase 2b clinical trial of Tesomet for the treatment of Prader-Willi syndrome (PWS), which is expected to initiate in the first half of 2021.
“There are currently no approved treatment options to manage hyperphagia, the uncontrollable hunger that is one of the most difficult symptoms of PWS, making clinical trials a high priority for the PWS community,” said John Walter, CEO of FPWR. “We are pleased to partner with Saniona on this program to empower patients to learn about the clinical trial process, ensure that the patient view is represented throughout the clinical trial continuum, and raise awareness of Saniona’s clinical trial within the PWS community.”
As part of the collaboration, Saniona and FPWR will conduct a webinar with the PWS community to provide information and answer questions about Saniona’s PWS clinical trial. FPWR will also utilize its online, email and social media platforms to raise awareness of Saniona’s clinical trial.
“We are grateful to partner with FPWR because one of our top priorities is to incorporate caregiver and patient feedback into our clinical trial actitvities to ensure we meet the needs of the PWS community,” said Rudolf Baumgartner, M.D., Chief Medical Officer and Head of Clinical Development at Saniona. “We look forward to working with FPWR to gather this feedback and to increase awareness of our clinical trial.”
Saniona previously evaluated Tesomet in a randomized, double-blind, placebo-controlled Phase 2a trial in adults and adolescents with PWS. Adult patients receiving Tesomet achieved a statistically significant reduction in hyperphagia, as well as a clinically meaningful reduction in body weight at a dose of 0.5 mg per day. A smaller study extension in an adolescent population showed that Tesomet appeared to be well tolerated at lower doses (0.125 mg/day and 0.25 mg/day) and suggested dose-dependent effects on weight and hyperphagia.
Saniona is currently planning to initiate a Phase 2b study of Tesomet in PWS in the first half of 2021. Saniona is also evaluating Tesomet for the treatment of hypothalamic obesity (HO) and plans to begin a Phase 2b trial in this indication in the first half of this year.
For more information, please contact
Trista Morrison, Chief Communications Officer, Saniona. Office: + 1 (781) 810-9227. Email: email@example.com
The information was submitted for publication, through the agency of the contact person set out above, at 14:00 CEST on 19 April 2021.
Saniona is a biopharmaceutical company focused on discovering, developing, and delivering innovative treatments for rare disease patients around the world. The company’s lead product candidate, Tesomet, is in mid-stage clinical trials for hypothalamic obesity and Prader-Willi syndrome, severe rare disorders characterized by uncontrollable hunger and intractable weight gain. Saniona’s robust drug discovery engine has generated a library now consisting of more than 20,000 proprietary modulators of ion channels, a significantly untapped drug class that is scientifically validated. Lead candidate SAN711 is entering Phase 1 for rare neuropathic disorders, with SAN903 for rare inflammatory and fibrotic disorders advancing through preclinical studies. Led by an experienced scientific and operational team, Saniona has an established research organization in Copenhagen, Denmark and is building its corporate office in the Boston, Massachusetts area, U.S. The company’s shares are listed on Nasdaq Stockholm Small Cap (OMX: SANION). Read more at www.saniona.com.
Tesomet is an investigational fixed-dose combination therapy of tesofensine (a triple monoamine reuptake inhibitor) and metoprolol (a beta-1 selective blocker). Saniona is advancing Tesomet for hypothalamic obesity and Prader-Willi syndrome, two severe rare disorders characterized by obesity and loss of appetite control. The programs are currently in clinical development. Saniona holds worldwide rights to Tesomet and is actively evaluating opportunities to advance this treatment globally.
About Prader-Willi Syndrome (PWS)
Prader-Willi syndrome (PWS) is recognized as the most common genetic cause of life-threatening obesity, with an estimated number of patients between 11,000 and 34,000 in the U.S. and between 17,000 and 50,000 in Europe. The disease results from a deletion or loss of function of a cluster of genes on chromosome 15, which leads to dysfunctional signaling in the brain’s appetite/satiety center (hypothalamus). Many of those affected with PWS suffer from insatiable appetite (hyperphagia); abnormal growth and body composition; low muscle tone (hypotonia); and social, emotional, or cognitive deficits. Hyperphagia is reported by caregivers to be among the most worrisome aspects of PWS, as this insatiable hunger persists no matter how much the patients eat and often requires caregivers to install locks on refrigerators and cabinets where food is stored. Many of those affected with PWS become morbidly obese and suffer shortened life expectancy and significant mortality. Common causes of mortality in PWS include respiratory disease, cardiac disease, infection, choking, gastric rupture, and pulmonary embolism. There are no medications approved specifically for the hyperphagia associated with PWS, and there is no cure for this disease. Treatment depends on symptoms and often includes hormone replacement. If obesity is avoided and complications are well managed, life expectancy for individuals with PWS is normal or near normal, and most individuals can lead healthy lives.
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
REC Silicon - First quarter 2021 results11.5.2021 06:55:00 CEST | Press release
Oslo, Norway – May 11, 2021: REC Silicon ASA (REC Silicon) reported first quarter 2021 revenues of USD 28.1 million versus USD 36.0 million in the fourth quarter of 2020 and EBITDA of USD 4.0 million versus USD 1.9 million in the prior quarter. REC Silicon reported a cash balance of USD 131.5 million on March 31, 2021 compared to USD 134.9 million on December 31, 2020. The Company reported EBITDA contributed by the semiconductor materials segment of USD 10.8 million for the first quarter compared to USD 8.0 million in the first quarter 2020 and USD 11.7 million for the fourth quarter of 2020. The decrease in EBITDA compared to the prior quarter was primarily the result of lower silicon gas sales volumes of 781 MT for the first quarter compared to 881 MT for the prior quarter. “The demand for semiconductor polysilicon and silicon gas has strengthened over the last quarters and we expect this trend to continue. Limited shipping availability over the Pacific has created some problems in f
Mandalay Resources Provides Target Release Date for First Quarter 2021 Financial Results and Conference Call10.5.2021 23:00:00 CEST | Press release
TORONTO, May 10, 2021 (GLOBE NEWSWIRE) -- Mandalay Resources Corporation (“Mandalay” or “the Company”) (TSX: MND, OTCQB: MNDJF) announces that its first quarter 2021 financial results will be released after market close on May 12, 2021, followed by a conference call with Dominic Duffy, President and Chief Executive Officer of Mandalay, for investors and analysts on May 13, 2021, at 8:00 AM (Toronto time). Analysts and interested investors are invited to participate using the following dial-in numbers: Participant Number:(201) 689-8341Participant Number (Toll free):(877) 407-8289Conference ID:13719805 A replay of the conference call will be available until 11:59 PM (Toronto time), May 27, 2021, and can be accessed using the following dial-in number: Encore Toll Free Dial-in Number:(877) 660-6853Encore ID:13719805 For Further Information: Dominic Duffy President and Chief Executive Officer Edison Nguyen Manager, Analytics and Investor Relations Contact: (647) 260-1566 About Mandalay Reso
Industrivärden divests its shareholding in SSAB for SEK 2,019 million10.5.2021 23:00:00 CEST | Press release
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA OR IN ANY JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT. Industrivärden has today divested its entire holding of 44,334,933 class A shares in SSAB at a price of SEK 45.53 per class A share, corresponding to a total proceeds of SEK 2,019 million. The divestment has been made by means of an accelerated book building process addressed to institutional investors. The divested shares represent 4.3 percent of the capital and 11.8 percent of the votes in SSAB. Commenting on the transaction, Industrivärden’s CEO Helena Stjernholm says: “Industrivärden has been a long-term and committed owner with a significant shareholding in SSAB since 1994. Within the framework of our ownership role, we have actively participated in several important development steps, s
Industrivärden avyttrar sitt aktieinnehav i SSAB för 2.019 mnkr10.5.2021 23:00:00 CEST | Pressemelding
EJ FÖR OFFENTLIGGÖRANDE, PUBLICERING ELLER SPRIDNING, DIREKT ELLER INDIREKT, I ELLER TILL USA, AUSTRALIEN, KANADA, JAPAN ELLER SYDAFRIKA ELLER ANNAN JURISDIKTION DÄR SÅDAN DISTRIBUTION ELLER PUBLICERING SKULLE VARA OLAGLIG. SE AVSNITTET VIKTIG INFORMATION I SLUTET AV DETTA PRESSMEDDELANDE. Industrivärden har idag avyttrat hela sitt aktieinnehav i SSAB om 44 334 933 A-aktier för 45,53 kronor per A-aktie, motsvarande en total försäljningslikvid om 2.019 mnkr. Avyttringen har skett genom en så kallad accelererad bookbuilding-process riktad till institutionella investerare. De avyttrade aktierna motsvarar 4,3 procent av kapitalet och 11,8 procent av röstetalet i SSAB. I en kommentar till försäljningen säger Industrivärdens vd, Helena Stjernholm: ”Industrivärden har varit en långsiktig och engagerad ägare med ett betydande aktieinnehav i SSAB sedan 1994. Inom ramen för vår ägarroll har vi aktivt deltagit i flera viktiga utvecklingssteg, såsom till exempel inriktningen mot produktområden med
CrossAmerica Partners LP Reports First Quarter 2021 Results10.5.2021 22:15:00 CEST | Press release
Allentown, PA, May 10, 2021 (GLOBE NEWSWIRE) -- CrossAmerica Partners LP Reports First Quarter 2021 Results Reported First Quarter 2021 Operating Loss of $0.9 million and Net Loss of $4.0 million compared to Operating Income of $77.4 million and Net Income of $72.1 million for the First Quarter 2020. During the First Quarter 2020, CrossAmerica recorded a gain on sale totaling $70.9 million, primarily driven by the sale of its 17.5% investment in CST Fuel SupplyGenerated First Quarter 2021 Adjusted EBITDA of $20.7 million and Distributable Cash Flow of $15.8 million compared to First Quarter 2020 Adjusted EBITDA of $25.3 million and Distributable Cash Flow of $20.4 millionReported First Quarter 2021 Gross Profit for the Wholesale Segment of $34.9 million compared to $35.1 million of Gross Profit for the First Quarter 2020Distributed 291.8 million wholesale fuel gallons during the First Quarter 2021 at an average wholesale fuel margin per gallon of 7.3 cents compared to 220.6 million who
The largest shareholder of JSC Olainfarm continues to maintain stake in the company10.5.2021 20:34:00 CEST | Press release
JSC Olainfarm has received information from the company Black Duck Invest a.s. registered in the Czech Republic that it has an intention to acquire the shares of JSC Olainfarm owned by Olmafarm Ltd., which makes up 42.56% of the shares of JSC Olainfarm. JSC Olainfarm has not received information that the transaction has taken place. According to the public information, Olmafarm Ltd. has approached the State Police and an investigation has been started. JSC Olainfarm has not been informed about changes in the register of shareholders in connection with the shares of JSC Olainfarm owned by Olmafarm Ltd. The Management Board of JSC Olainfarm actively monitors the situation and will continue to provide information in accordance with the legal requirements. JSC Olainfarm, a part of Olainfarm Group, is one of the leading pharmaceutical companies in the Baltic States offering high quality medicine and chemical pharmaceutical products. The business strategy “FORWARD” highlights the company’s m
Nokia selected by Movistar Chile for commercial 5G network launch10.5.2021 20:00:00 CEST | Press release
Press Release Nokia selected by Movistar Chilefor commercial 5G network launch Movistar Chile’s commercial 5G network to launch with Nokia’s AirScale technology The deal upgrades Telefónica’s 4G and 4G+ network across several Chilean cities; option for a seamless upgrade to 5G services in the future This high-speed mobile technology will be supported by Movistar Chile's fiber optics, which will allow the different mobile antennas deployed in cities to be interconnected May 10, 2021 Espoo, Finland – Nokia has today announced that it has been chosen by Telefónica’s Latin America brand, Movistar Chileto provide equipment from its AirScale portfolio to launch the operator’s 5G network in the country. This milestone deployment will enable 5G services for Movistar customers. In addition, Nokia will upgrade Movistar’s 4G and 4G+ networks to strengthen the critical network backbone across Chile’s key markets. To meet the demands from consumers and businesses for improved speeds and enhanced se